Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthopediatrics (KIDS) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Orthopediatrics (KIDS) over the last 10 years, with Q3 2025 value amounting to $99.2 million.

  • Orthopediatrics' Non-Current Debt rose 3676.53% to $99.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.2 million, marking a year-over-year increase of 3676.53%. This contributed to the annual value of $73.0 million for FY2024, which is 63633.43% up from last year.
  • Orthopediatrics' Non-Current Debt amounted to $99.2 million in Q3 2025, which was up 3676.53% from $97.0 million recorded in Q2 2025.
  • Orthopediatrics' 5-year Non-Current Debt high stood at $99.2 million for Q3 2025, and its period low was $650000.0 during Q3 2023.
  • In the last 5 years, Orthopediatrics' Non-Current Debt had a median value of $1.0 million in 2021 and averaged $25.5 million.
  • As far as peak fluctuations go, Orthopediatrics' Non-Current Debt crashed by 9783.89% in 2023, and later soared by 1105600.0% in 2024.
  • Orthopediatrics' Non-Current Debt (Quarter) stood at $907000.0 in 2021, then fell by 15.88% to $763000.0 in 2022, then soared by 1198.56% to $9.9 million in 2023, then soared by 636.33% to $73.0 million in 2024, then soared by 35.94% to $99.2 million in 2025.
  • Its Non-Current Debt stands at $99.2 million for Q3 2025, versus $97.0 million for Q2 2025 and $73.0 million for Q1 2025.